FKBP12, the 12-kDa FK506-binding protein, is a ubiquitous abundant protein
that acts as a receptor for the immunosuppressant drug FK506, binds tightly
to intracellular calcium release channels and to the transforming growth f
actor beta (TCF-beta) type I receptor. We now demonstrate that cells from F
KBP12-deficient (FKBP12(-/-)) mice manifest cell cycle arrest in G(1) phase
and that these cells can be rescued by FKBP12 transfection. This arrest is
mediated by marked augmentation of p21(WAF1/CIP1) levels, which cannot be
further augmented by TGF-beta1. The p21 up-regulation and cell cycle arrest
derive from the overactivity of TGF-beta receptor signaling, which is norm
ally inhibited by FKBP12. Cell cycle arrest is prevented by transfection wi
th a dominant-negative TGF-beta receptor construct. TGF-beta receptor signa
ling to gene expression can be mediated by SMAD, p38, and ERK/MAP kinase (e
xtracellular signal-regulated kinase/mitogen-activated protein kinase) path
ways. SMAD signaling is down-regulated in FKBP12(-/-) cells. Inhibition of
ERK/MAP kinase fails to affect p21 up-regulation. By contrast, activated ph
osphorylated p38 is markedly augmented in FKBP12(-/-) cells and the p21 up-
regulation is prevented by an inhibitor of p38. Thus, FKBP12 is a physiolog
ic regulator of cell cycle acting by normally down-regulating TGF-beta rece
ptor signaling.